{"id":"intravenous-topotecan-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topotecan is a topoisomerase I inhibitor that prevents DNA religation, leading to DNA damage and apoptosis. Cisplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, causing irreversible DNA damage. The combination exploits synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:53.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Small cell lung cancer"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT01076400","phase":"PHASE1, PHASE2","title":"A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-31","conditions":"Cervical Cancer","enrollment":7},{"nctId":"NCT02786719","phase":"NA","title":"High-Risk Neuroblastoma Chemotherapy Without G-CSF","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00320359","phase":"PHASE3","title":"Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-08","conditions":"Lung Cancer, Small Cell","enrollment":700},{"nctId":"NCT02339753","phase":"PHASE2","title":"Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The Korean Society of Pediatric Hematology Oncology","startDate":"2015-01","conditions":"Pediatric Solid Tumor","enrollment":24},{"nctId":"NCT00826891","phase":"PHASE2","title":"Study of Cisplatin in Cervical Cancer Stage IVB","status":"UNKNOWN","sponsor":"Chinese Anti-Cancer Association","startDate":"2009-02","conditions":"Cervical Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous topotecan/cisplatin","genericName":"Intravenous topotecan/cisplatin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms. Used for Ovarian cancer, Small cell lung cancer, Cervical cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}